Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biphasic insulin aspart in type 2 diabetes
NCT00282451Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2006
- Primary completion
- Aug 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 14 weeks. Started Feb 2006; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00282451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282451.